FDA has heeded a recommendation by scientific experts and agreed that “associated distress” may be a co-primary endpoint for clinical trials of drugs intended to treat low sexual interest, desire, and/or arousal disorders, in the place of number of “satisfying sexual events.”
The agency noted its acceptance of this co-primary endpoint in its just-released draft guidance, "Low Sexual Interest, Desire, and/or Arousal in Women: Developing Drugs for Treatment